Supervisor Database Search
Guidance for ICAT Supervisors
The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year.
You can read about the ICAT supervisor selection process and eligibility criteria below:
Terms of reference/guide to supervising ICAT Fellows.
You can read the terms of reference for supervisors actively supervising ICAT Fellows below:
Supervisor Database
Search for supervisors below. You can filter your search using the options and select multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.
Full NameDr Kenneth Nally
School of Biochemistry and Cell Biology
University College Cork
Webpage:apc.ucc.ie
Email hidden; Javascript is required.
- genetics, genomics and molecular biology
- infectious disease and the immune system
- cell and developmental biology/regenerative medicine
- physiology and non-communicable disease
- cancer/oncology
- Medicine
- Surgery
- Gastroenterology
- Infectious diseases
- Immunology
- Oncology
Research Interests:
Host-Microbe Interaction, Inflammation, and Cancer Biology
(1) Host-Microbe interactions in health and inflammatory disease
(2) Immunopathology in inflammatory disease and cancer
(3) Mechanisms underpinning cross-talk and synergism between inflammatory signalling pathways
(4) Specific focus on Interferon (IFN) and Tumor Necrosis Factor (TNF) signalling pathways
(5) Crosstalk between inflammatory and oncogenic signalling pathways
(6) Epigenetic mechanisms underpinning regulation of inflammatory, anti-viral and oncogenic gene expression
(7) Functional genomics analysis of inflammatory, cell survival and cell death pathways
(8) Discovery of cancer cell intrinsic tumour suppressor mechanisms underpinning immune-mediated suppression of cancer
My group's research interests are in the areas of Host-Microbe Interaction, Inflammation and Cancer Biology. Our group is exploring the molecular and cellular mechanisms underpinning the role of the immune system in host recognition of microbes, chronic inflammatory diseases such as Inflammatory Bowel Disease (IBD), type I diabetes and colon cancer. In terms of IBD and colon cancer, our research group is particularly interested in how the relative sensitivity and resistance of intestinal epithelial cells and colon cancer cells to immune-mediated apoptosis contributes to disease pathogenesis and response to therapeutic interventions. The molecular mechanisms - signal transduction, transcriptional regulation and epigenetic - underpinning the regulation of gene expression in response to inflammatory stimuli in immune, non-immune cells and cancer cells and how this contributes to disease pathogenesis is the main focus of our research. Specifically, they have an interest in understanding how the synergistic interactions between IFN-gamma and other inflammatory stimuli such as TNF-alpha both in terms of their overall effect on inflammatory gene expression and also cell fate decisions contribute to pathogenesis in diseases such as IBD, type I diabetes and other inflammatory conditions.
It is well appreciated that in IBD and type I diabetes, pro-inflammatory cytokines (IFN-gamma and TNF-alpha) induce the death of epithelial cells thereby compromising the function of the gut and the pancreas respectively. Currently, in the context of collaborations with academic and pharmaceutical groups we are investigating the possible roles of signalling pathways and epigenetic modifiers in regulating inflammatory gene expression and cell fate decisions in response to these and other stimuli.
We use a combination of in vitro cell and molecular biology based approaches, functional genomics approaches, in vivo based animal models of inflammation, inflammation linked colon cancer, human biopsy tissue and primary cultures of human organoids 'mini-guts' to investigate basic mechanisms of disease with a focus on inflammatory bowel disease. In addition they use these various systems for drug target identification, drug target validation studies and for pre-clinical profiling of novel drug candidates for efficacy in the setting of chronic intestinal inflammation. They also have ongoing active research projects in the areas of host microbe interactions with a particular interest in the mechanisms underpinning interaction of host cells with gut commensal bacteria.